Showing results (41-50 of 90) with videos related to
Sort By:
Pageof 9
Clinical Genitourinary Cancer|August 15, 2015
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)Michael A Carducci, Judith Manola, Suresh G Nair, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92)Peter H Wiernik, Janice P Dutcher, Xiapan Yao, et al.Cancer|January 9, 2019
Association between age and sex and mortality after adjuvant therapy for renal cancerRonac Mamtani, Xin Victoria Wang, Bishal Gyawali, et al.Journal for Immunotherapy of Cancer|September 25, 2019
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, et al.Urology|December 11, 2007
Renal medullary carcinoma: the Bronx experienceA Ari Hakimi, Phillip T Koi, Paul M Milhoua, et al.Medical Oncology (Northwood, London, England)|September 30, 2003
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)Janice P Dutcher, Jason P Fine, Robert L Krigel, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitutionJanice P Dutcher, Donna Neuberg, Michael B Atkins, et al.Investigational New Drugs|January 7, 2004
Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology GroupKeith Stuart, Donna E Levy, Tom Anderson, et al.Cancer Immunity|March 10, 2006
Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated TnKevin P O'Boyle, Susan Coatsworth, Gillian Anthony, et al.Medical Oncology (Northwood, London, England)|February 21, 2009
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologiesJanice P Dutcher, Paul de Souza, David McDermott, et al.Pageof 9